IMMUCOR INC
BLUD evidence brief
What we can confirm
- BioSniper Score:
- 7.3 / 10
- Lead Asset:
- mia fora ngs (Approved)
What it means
What to watch
Prepared research question
What matters most for BLUD—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
mia fora ngs (Approved)
Next Catalyst
—
Tracking 2 pipeline candidates for IMMUCOR INC.
Run IMMUCOR INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available IMMUCOR INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Approved
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Frequently asked questions
What is IMMUCOR INC's lead drug candidate?
IMMUCOR INC's most advanced tracked candidate is mia fora ngs (Approved) for High resolution typing for transplants.
What therapeutic areas does IMMUCOR INC focus on?
IMMUCOR INC develops therapies across Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.